ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer
Public ClinicalTrials.gov record NCT04662580. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase 1 study to assess the safety and tolerability of ARX517 as monotherapy or combination therapy in adult subjects with metastatic prostate cancer (mPC).
Study identification
- NCT ID
- NCT04662580
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 183 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 3, 2021 (Actual)
- Primary completion
- Dec 31, 2026 (Estimated)
- Completion
- Dec 31, 2026 (Estimated)
- Last update posted
- Sep 28, 2026
2021 – 2026
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UC San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| University of California, Los Angeles School of Medicine | Los Angeles | California | 90095-3000 | — |
| UCSF Medical Center at Mission Bay | San Francisco | California | 94143-2350 | — |
| Winship Cancer Institute of Emory University | Atlanta | Georgia | 30322 | — |
| Indiana University Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | 46202-5116 | — |
| University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | 48109-5000 | — |
| Washington University St. Louis School Medicine Siteman Cancer Center | St Louis | Missouri | 63110 | — |
| GU Research Network | Omaha | Nebraska | 68130 | — |
| Weill Cornell Medical College | New York | New York | 10021-5663 | — |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| Carolina Urologic Research Center | Myrtle Beach | South Carolina | 29572 | — |
| University of Washington | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04662580, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 28, 2026 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04662580 live on ClinicalTrials.gov.